The molecular basis of monogenic hypocholesterolemia informs both its own management and the development of novel lipid-lowering therapies like PCSK9 and ANGPTL3 inhibitors.
Answers are grounded in this paper and cite their sources.
May guide early vitamin and dietary management in monogenic hypocholesterolemia; extends genetic insights to PCSK9 and ANGPTL3 inhibitor development.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: